PharmaBlock, an innovative chemistry products and services provider, has appointed Dr. Xudong Wei as senior vice president and head of CDMO Business to enhance small molecule CDMO capabilities and speed up the business.
 
Wei’s scientific and management career stretches back to over twenty years ago. Prior to joining PharmaBlock, he served at both global top pharmaceutical and CDMO companies, where he worked with over 80 global pharmaceutical and biotech companies on more than 130 drug substance projects. Previously, he worked at Boehringer Ingelheim Pharmaceuticals Inc. for more than 15 years and led the process development and GMP manufacturing projects from clinical to commercialization.
 
At PharmaBlock, Wei will be responsible for the strategic development and operational management of the CDMO section, ensuring that PharmaBlock offers fast, high-quality, and cost-effective solutions to advance partners’ projects smoothly.
 
“Dr. Xudong Wei is an important addition to our leadership team. He has strong industry background and experience across China, US, and Europe. His extensive expertise brings our team a wealth of knowledge and unique customer perspective,” commented Dr. Minmin Yang, chairman and CEO of PharmaBlock, “The scientific and strategic leadership provided by Dr. Wei and the senior expert and management team will enable the team to deliver better services to our partners and support them to realize the next generation of drug development innovation.”
 
Other Recent Appointments
 
The appointments demonstrate the priority that PharmaBlock places on attracting vital talents to lead and innovate essential CMC functions.
 
In 2020, Dr. Wenfang Miao joined PharmaBlock as senior vice president of Quality. She brings over two decades of research and management experience in analytical R&D, quality control, quality assurance, and CMC regulatory affairs at GSK and Elan Pharmaceuticals, and held leadership positions as senior vice president of Quality and Regulatory Affairs at Pharmaron and vice president at Wuxi STA Pharmaceuticals.
 
Over the past years, PharmaBlock has recruited a number of industry veterans, driving the improvement of the key capabilities from discovery process research, clinical-stage development, continuous optimization towards commercialization, GMP production, new technologies, quality compliance, and CMC filing support, etc.